<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661943</url>
  </required_header>
  <id_info>
    <org_study_id>CDB0369</org_study_id>
    <nct_id>NCT04661943</nct_id>
  </id_info>
  <brief_title>Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>oubai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II，single arm，open-label study to assess Maintenance Therapy of Chidamide in Patients&#xD;
      With Hepatitis B Virus（HBV）Positive Diffuse Large B-cell Lymphoma with complete response&#xD;
      after completion of prior chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective to evaluate the efficacy and safety of maintenance therapy with Chidamide in&#xD;
      patients With Hepatitis B Virus（HBV）Positive Diffuse Large B-cell Lymphoma（DLBCL） with&#xD;
      complete response after completion of prior chemotherapy, so as to provide the basis for the&#xD;
      application of Chidamide in HBV positive DLBCL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6months</time_frame>
    <description>Progression-free survival（by IWC）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucidinostat</intervention_name>
    <description>Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Chidamide，CS055，HBI-8000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histopathology confirmed DLBCL，with chronic hepatitis B before treatment&#xD;
&#xD;
          -  After systemic treatment, complete response has been achieved and complete response&#xD;
             lasted within 1year before enrollment&#xD;
&#xD;
          -  The expected chemotherapy was completed and the laboratory indexes returned to normal&#xD;
&#xD;
          -  The absolute value of neutrophil ≥ 1.5 × 10 9 / L, platelet count≥ 90 × 10 9 / L,&#xD;
             hemoglobin level≥ 90 g / L&#xD;
&#xD;
          -  Patients who cannot undergo hematopoietic stem cell transplantation for various&#xD;
             reasons&#xD;
&#xD;
          -  18-75 years old, both male and female&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  Body weight: male 67 ± 20 kg (47-87 kg), female 55 ± 20 kg (35-75 kg)&#xD;
&#xD;
          -  expected survival time ≥3 months&#xD;
&#xD;
          -  Voluntary written informed consent prior to trail screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women and women of childbearing age who are unwilling to take&#xD;
             contraceptive measures&#xD;
&#xD;
          -  Patients with prolonged QTc interval (male &gt; 450ms, female &gt; 470ms), ventricular&#xD;
             tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI)&#xD;
             within 1 year, congestive heart failure (CHF), and coronary heart disease with&#xD;
             symptoms requiring drug treatment&#xD;
&#xD;
          -  B-ultrasound showed that the width of the fluid dark area in the pericardial cavity&#xD;
             was ≥ 10 mm at the end of diastolic period&#xD;
&#xD;
          -  Patients with previous or planned organ transplantation&#xD;
&#xD;
          -  Patients receiving symptomatic treatment for early myelotoxicity within 7 days before&#xD;
             enrollment&#xD;
&#xD;
          -  HBV nucleic acid quantitation &gt; 103 IU / ml&#xD;
&#xD;
          -  Patients with active bleeding&#xD;
&#xD;
          -  Patients with thrombosis, embolism, cerebral hemorrhage, cerebral infarction and other&#xD;
             this kind of diseases or medical history&#xD;
&#xD;
          -  Patients with active infection or persistent fever within 14 days before enrollment&#xD;
&#xD;
          -  less than 6 weeks after major organ surgery&#xD;
&#xD;
          -  Abnormal liver function [total bilirubin &gt; 1.5 times of the upper limit of normal&#xD;
             value; ALT / AST &gt; 2.5 times of upper limit of normal value for patients without liver&#xD;
             metastasis ; ALT / AST &gt; 5 times of upper limit of normal value for patients with&#xD;
             liver metastasis ], abnormal renal function (serum creatinine &gt; 1.5 times of upper&#xD;
             limit of normal value)&#xD;
&#xD;
          -  Mental disorders/Those who cannot obtain informed consent&#xD;
&#xD;
          -  Patients with drug abuse and long-term alcohol abuse that affect evaluation&#xD;
&#xD;
          -  The investigator determined not suitable to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ou BAI, doctor</last_name>
    <phone>13039046656</phone>
    <email>oubai16@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ou BAI, doctor</last_name>
      <phone>13039046656</phone>
      <email>oubai16@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>oubai</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

